Consistent with prior findings from our group and others, GH signaling has been implicated in promoting anticancer therapy resistance through multiple molecular mechanisms, including the induction of ATP-binding cassette (ABC) multidrug transporters and epithelial-to-mesenchymal transition (EMT) transcription factors across various cancers [9,10,11,16,25]. The gene discussed is GH1; the disease is cancer.